Plus Therapeutics (PSTV) Expected to Release Quarterly Earnings on Thursday

by · The Markets Daily

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) is projected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Plus Therapeutics to post earnings of ($0.88) per share and revenue of $1.1130 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.97 million. On average, analysts expect Plus Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Plus Therapeutics Stock Performance

Shares of PSTV opened at $3.84 on Wednesday. The stock has a 50 day moving average price of $4.23 and a 200 day moving average price of $5.50. Plus Therapeutics has a one year low of $2.90 and a one year high of $23.42. The stock has a market capitalization of $26.43 million, a price-to-earnings ratio of -1.67 and a beta of 1.40.

Hedge Funds Weigh In On Plus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSTV. Geode Capital Management LLC grew its holdings in Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the 4th quarter valued at about $525,000. Virtu Financial LLC acquired a new position in shares of Plus Therapeutics during the 4th quarter valued at about $254,000. State Street Corp grew its holdings in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Plus Therapeutics in the fourth quarter valued at about $127,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Analysts Set New Price Targets

PSTV has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Friday, July 17th. Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Plus Therapeutics has an average rating of “Hold” and an average price target of $56.40.

View Our Latest Research Report on PSTV

About Plus Therapeutics

(Get Free Report)

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.

Read More